Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVd Followed by DId for Relapsed/Refractory Multiple Myeloma
NCT03763162Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib, dexamethasone and ixazomib in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival up to 18 months. Started Jan 2019; status: active, not recruiting.
02
Drugs
daratumumabbortezomibdexamethasoneixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03763162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763162.